UK Sleep-Wake Disorder Market Size to Reach $2.3 Billion by 2035

UK sleep-wake disorder market is projected to grow from $1.3 billion in 2025 and is projected to reach $2.3 billion by 2035, growing at a CAGR of 6.3% during the forecast period 2026-2035. The UK sleep-wake disorder market is shaped by a growing recognition of sleep as a core component of overall health, alongside rising awareness of conditions such as insomnia, sleep apnea, circadian rhythm disruption, and excessive daytime sleepiness. Increasing lifestyle pressures, irregular work patterns, and higher stress levels are contributing to a greater incidence of sleep disturbances, which in turn is supporting demand for diagnostic and treatment solutions. At the same time, limited access to specialized sleep clinics and variability in diagnosis rates continue to influence how patients are identified and managed within the healthcare system. The market is also being supported by the gradual integration of sleep health into broader mental health discussions, encouraging earlier screening and intervention across primary care settings.

Browse the full report description of “UK Sleep-Wake Disorder Market Size, Share & Trends Analysis By Disorder Type (Insomnia, Hypersomnia, Sleep Apnea, Circadian Rhythm Sleep-Wake Disorders, Parasomnias, Dyssomnias, and Others), By Treatment Type (Pharmacological Therapy, Behavioral Therapy, Light Therapy, Device-Based Therapy, and Others), By Diagnosis & Management Approach (Polysomnography & Sleep Studies, Actigraphy-Based Monitoring, Clinical Evaluation & Screening Tools, and Remote/Digital Sleep Monitoring Solutions), and By Application (Hospitals, Home Care Settings, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/uk-sleep-wake-disorder-market

Technological adoption is emerging as a key driver in the UK sleep-wake disorder market, with greater use of home-based diagnostic tools, wearable monitoring systems, and digital health platforms enabling more continuous assessment of sleep patterns. There is also a shift toward personalized treatment approaches, supported by improved understanding of neurobiological mechanisms regulating sleep and wakefulness. Pharmacological innovation, including newer treatment classes targeting wake-promoting pathways, is gradually expanding available therapeutic options, although access and prescribing practices remain uneven. Additionally, increasing emphasis on remote care models and artificial intelligence-assisted diagnostics is influencing how healthcare providers manage long-term sleep disorder care pathways.

Competitive Landscape of the Sleep-Wake Disorder Market

The key players in the sleep-wake disorder market are GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, Jazz Pharmaceuticals plc, and Pfizer Inc., among others. The competitive landscape of the sleep-wake disorder market is influenced by established pharmaceutical companies that focus on central nervous system therapies and neurobiology-driven drug development. These players are actively engaged in expanding treatment options targeting insomnia, excessive daytime sleepiness, and related neurological sleep disturbances through both novel molecules and reformulated therapies. Strategic emphasis is also placed on clinical research aimed at improving safety profiles, reducing dependency risks, and enhancing long-term patient adherence. In addition, collaborations and pipeline diversification efforts are shaping advancements in precision-based and mechanism-specific sleep disorder treatments.

• In April 2024, the Scottish Medicines Consortium (SMC) approved restricted NHS use of QUVIVIQ® (daridorexant) for adults with chronic insomnia who have failed or cannot access CBT-I.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Disorder Type
  • By Treatment Type
  • By Diagnosis & Management Approach
  • By Application
• Competitive Landscape - GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, Jazz Pharmaceuticals plc, and Pfizer Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

UK Sleep-Wake Disorder Market Report Segment

By Disorder Type

• Insomnia
• Hypersomnia
• Sleep Apnea
• Circadian Rhythm Sleep-Wake Disorders
• Parasomnias
• Dyssomnias
• Others

By Treatment Type

• Pharmacological Therapy
• Behavioral Therapy
• Light Therapy
• Device-Based Therapy
• Others

By Diagnosis & Management Approach

• Polysomnography & Sleep Studies
• Actigraphy-Based Monitoring
• Clinical Evaluation & Screening Tools
• Remote / Digital Sleep Monitoring Solutions

By Application

• Hospitals
• Home Care Settings
• Others

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uk-sleep-wake-disorder-market